Archive for February, 2015

Lets Play~ The Sims 3 Perfect Genetics Challenge~ Ep.1 "Our Personal Baby Factory"
Thanks for watching another lets play about baby making! ~ Remember that the content that is said or done is all for entertainment purposes. None of which should be taken seriously! Enjoy...

By: FaictheCake

See the article here:
Lets Play~ The Sims 3 Perfect Genetics Challenge~ Ep.1 "Our Personal Baby Factory" - Video

Menu 14 Review - Human Genetics
This video is a synopsis of chapter 14 and highlights the major topics: karyotypes, genetic diseases, pedigree analysis, sex-linked traits, and nondisjunction.

By: MrDBioCFC

See original here:
Menu 14 Review - Human Genetics - Video

Cancer researchers at Indiana University report that about 15 percent of people with pancreatic cancer may benefit from therapy targeting a newly identified gene signature.

Using data from the Cancer Genome Atlas, Murray Korc, M.D., the Myles Brand Professor of Cancer Research at the Indiana University School of Medicine and a researcher at the Indiana University Melvin and Bren Simon Cancer Center, and colleagues found that a sub-group of pancreatic cancer patients who possess a strong angiogenic gene signature could benefit from personalized therapies that cut off the pathways that feed the cancer's growth.

This particular gene signature enables abnormal blood vessels to form in tumors, which feeds the tumor's growth.

The finding, published online Feb. 25 in the journal Oncotarget, is new because the prevalence of this signature was not previously known. The authors also demonstrated for the first time that endothelial cells, the main type of cell found in the inside lining of blood vessels, can produce molecules that directly stimulate the growth of pancreatic cancer cells.

"We showed that endothelial cells can stimulate the growth of pancreatic cancer cells and that by silencing or inhibiting certain pathways -- JAK1-2 and STAT3 -- we can alter that effect," Dr. Korc explained. "We demonstrated that it is possible to target these pathways and prolong the survival of genetically modified mice whose pancreatic cancers also have a strong pro-angiogenic gene signature."

Thus, for people with a strong pro-angiogenic gene signature, the finding suggests that they may benefit from targeted therapy that is directed against one of these pathways.

An important feature of the study was to demonstrate that it is possible to implant in mice small biopsy samples obtained from patients undergoing endoscopic procedures and to generate human tumors in these mice. When the original human tumor had evidence for angiogenesis, the implanted human tumor also exhibited angiogenesis in the mouse. Additional studies are necessary to confirm that these approaches could guide the design of precision medicine using targeted therapies, Dr. Korc said.

The need for new therapies for pancreatic cancer patients is great as only 7 percent of people with the disease survive more than five years after diagnosis. According to the American Cancer Society, there will be an estimated 48,960 new cases of pancreatic cancer and 40,560 deaths from the disease in 2015.

Co-authors of the study were Jesse Gore, Ph.D.; Stuart Sherman, M.D.; Harvey Cramer, M.D.; Hai Nguyen, M.D.; Kelly Craven, Monica Cheng, and Julie Wilson, all of IU School of Medicine, and Gregory Cote M.D. M.S., formerly of IU School of Medicine and now at the Medical University of South Carolina.

The study was made possible, in part, by grant CA-075059 awarded by the National Cancer Institute of the National Institutes of Health.

See the original post:
Pancreatic cancer patients who benefit from personalized treatment identified

Bengaluru:Feb 27, 2015, DHNS

Two courses of stem cell therapy have helped Ashok Kumar, 59, who suffered from tremors and rigidity due to Parkinsons disease, recover completely, much to the joy of his family. The man was brought inside my cabin in a wheelchair. He was unable to even sit on the chair without support. Today, he walks independently. Stem cell therapy has made it possible for him, said Dr Naseem Sadiq, Director, Plexus Neuro and Stem Cell Research Centre, who began treating Kumar in October, last year.

Previously, medication and surgical procedure were the only treatment option for Parkinsons disease. Medication in the long-term often lacks effectiveness and may cause side effects, while surgery is not always feasible. Lately, stem cell therapy has turned out to be a boon for patients with Parkinsons, Dr Sadiq said.

Kumar is among the few who have benefited from stem cell therapy. However, though the State has been reporting an increase in the number of registered stem cell donors, it is far behind sufficient as the genetic match between donor and recipient could be anywhere between one in 10,000 and one in two million, according to experts.

Speaking to Deccan Herald, Raghu Rajgopal, co-founder, Datri, a registry for stem cell donation, said, The response we get from Karnataka when we conduct stem cell camps is great. We see a lot of people and registering with us.

As many as 6,000 people have registered from the State under the Datri registry. A total of 72,000 people have registered across the country. In Kerala, 11,000 have signed up, the highest so far, he said.

Among the common myths are that by donating stem cells one turns infertile and weak, have increased chances of cancer and also that there would be excess loss of blood, he said.

According to studies, over one lakh people are diagnosed with Leukemia (blood cancer) and other blood disorders every year in India. The Indian Council of Medical Research has predicted that by the end of 2015, Leukemia cases will reach an estimated 1,17,649 and 1,32,574 by 2020. Stem cell therapy is a widely used treatment mechanism for Leukemia.

Go to Top

View original post here:
Stem cell therapy a boon to Parkinson's patients

Almost all injuries, even minor skin scratches, trigger an inflammatory response, which provides protection against invading microbes but also turns on regenerative signals needed for healing and injury repair -- a process that is generally understood but remains mysterious in its particulars.

Writing in the February 25 online issue of Nature, an international team of scientists, headed by researchers at the University of California, San Diego School of Medicine, report finding new links between inflammation and regeneration: signaling pathways that are activated by a receptor protein called gp130. "We found that gp130 is capable of activating several signaling pathways that turn on a number of transcription factors known to have a key role in stem cell biology," said the study's lead author, Koji Taniguchi, MD, PhD, assistant project scientist in the Department of Pharmacology at UC San Diego.

These transcription factors -- specifically STAT3, YAP and Notch -- stimulate the proliferation and survival of normal tissue stem cells, which lead to healing and repair, said senior author Michael Karin, PhD, Distinguished Professor Pharmacology and Pathology and head of UC San Diego's Laboratory of Gene Regulation and Signal Transduction.

"While the work was mainly conducted on a mouse model of intestinal injury, similar to the one that underlies human inflammatory bowel disease (IBD), we provide evidence that the same mechanism may control liver regeneration, which suggests a general role in tissue repair," said Karin.

In addition to explaining a key biomedical phenomenon, the researchers said the findings have important clinical implications for the treatment of IBD and colorectal cancer. The major signal sensed by gp130 is the inflammatory hormone (cytokine) IL-6 and closely related proteins. Expression of IL-6 has been found to be elevated in IBD, both in Crohn's disease and ulcerative colitis, giving rise to the possibility that inhibition of IL-6 binding to its receptor -- a complex between gp130 and a specific IL-6 binding protein -- may ameliorate the pathology of IBD.

But just the opposite has been observed. Drugs that block the binding of IL-6 to its receptor complex actually increase the risk of intestinal perforation and bleeding, making them unsuitable for the treatment of IBD. The new work suggests that IL-6 and the signaling pathways it stimulates are not the cause of IBD, but are part of the natural protective reaction to the initial injury and inflammatory response associated with the onset of IBD.

The Taniguchi and Karin team say it is important that future treatments not interfere with the healing response triggered by IL-6 and gp130. Nonetheless, the same pathways involved in healing and regeneration can go awry and become chronically stimulated in colorectal cancer.

The new work defines several molecular targets suitable for development of new targeted therapies for this very common malignancy -- the third leading cause of cancer-related death, though Karin cautioned that "such treatments should not be combined with conventional and highly toxic anti-cancer drugs whose major side effect is damage and inflammation of the intestinal mucosa, a disease known as mucositis that will only be exacerbated by blocking the regenerative response triggered by IL-6."

Story Source:

The above story is based on materials provided by University of California, San Diego Health Sciences. The original article was written by Scott LaFee. Note: Materials may be edited for content and length.

Read the rest here:
Link between inflammation, tissue regeneration and wound repair response

Contact Information

Available for logged-in reporters only

Newswise LA JOLLA, CA February 25, 2015 A new study led by researchers at The Scripps Research Institute (TSRI) and the University of California (UC), San Diego School of Medicine shows that certain stem cell culture methods are associated with increased DNA mutations. The study points researchers toward safer and more robust methods of growing stem cells to treat disease and injury.

This is about quality control; were making sure these cells are safe and effective, said Jeanne Loring, a professor of developmental neurobiology at TSRI and senior author of the study with Louise Laurent, assistant professor at UC San Diego.

Laurent added, The processes used to maintain and expand stem cell cultures for cell replacement therapies needs to be improved, and the resulting cells carefully tested before use.

The findings were published February 25 in the open-access journal PLOS ONE.

Growing Stem Cells

Because these human stem cells, called "pluripotent stem cells," can differentiate into many types of cells, they could be key to reversing degenerative diseases, such as Parkinsons disease, or repairing injured tissue, such as cardiac muscle after a heart attack. Stem cells are relatively rare in the body, however, so researchers must culture them in dishes.

While all cells run the risk of mutating when they divide, previous research from Loring and her colleagues suggested that stem cell culturing may select for mutations that favor faster cell growth and are sometimes associated with tumors.

Most changes will not compromise the safety of the cells for therapy, but we need to monitor the cultures so that we know what sorts of changes take place, said the papers first author Ibon Garitaonandia, a postdoctoral researcher working in Lorings lab at the time of the study.

Go here to see the original:
New Study Shows Safer Methods for Stem Cell Culturing

February 25, 2015

Credit: Thinkstock

Chuck Bednar for redOrbit.com @BednarChuck

Scientists from the UK and Israel have demonstrated for the first time that it is possible to make human egg and sperm cells using skin from two adults of the same sex a breakthrough that may make it possible for same-sex couples to have children with shared DNA.

The research, which was funded by the Wellcome Trust, was completed at Cambridge University with the assistance of experts from the Weizmann Institute of Science, Cambridge News reported on Monday. They were able to use stem cell lines from embryos and from five different adults (a total of 10 different donor sources) to successfully create germ-cell lines.

According to CBS Atlanta, the experiment had previously been successful in creating live baby mice, but this new study marks the first time in which engineered human cells were found to be an identical match to aborted fetuses. It also marks the first time that human stem and skin cells were combined to form entirely new germ-cell lines.

[STORY: FDA reconsidering ban on homosexual, bisexual blood donors]

We have succeeded in the first and most important step of this process, which is to show we can make these very early human stem cells in a dish, Azim Surani, project leader at the Wellcome Trust and a professor of physiology and reproduction at Cambridge, told The Sunday Times.

Hope for those who cant conceive

The key to the process was SOX17, a master gene which typically works to direct stem cells to form whatever type of tissue or organ is required. Their new process works by manipulating this gene so that it becomes part of a primordial germ cell specification (causing it to create cells that will form an entire person), making it possible to create primordial germ cells in the lab.

Go here to see the original:
Sperm and egg created from skin cells of two same sex adults

While well known for its unique electromechanical properties, graphene may also prove key in preventing cancer tumor recurrence. A drawback of traditional cancer treatment with radiation and chemotherapy is that the primary developmental source of future tumors is not eradicated. Cancer stem cells, or CSCs, can survive treatment and give rise to recurring tumors, metatasis, and drug resistance after repeated treatments. Researchers from the University of Manchester and the University of Calabria have discovered that graphene oxides targets and neutralize CSCs in a manner that is not yet fully understood.

One CSC can develop into a ball of new CSCs called a tumor-sphere, or into new tumor cells, such as what happens in metastasis. They're immortal, divide rapidly, and resist stress. A potential solution? Graphene oxide, GO, which is an oxidized form of its well-known carbon cousin and soluble in many solvents.

For a complete look at the efficacy of GO across cancers, researchers used CSCs from six types of cancer: breast, pancreatic, lung, brain, ovarian and prostate. They also used normal skin cells to confirm that GO would not be toxic to the body.

After cells were treated for 48 hours with a GO solution, the researchers found that not only did GO interrupt the ability of CSCs in all cancer types to proliferate by forming spheres, but that GO was safe to the skin cells.

Dr Aravind Vijayaraghavan of the National Graphene Institute at the University of Manchester says that GO seems to force the cancer stem cells to differentiate into non-cancer stem cells. In this way, GO effectively takes the CSC out of commission for creating future tumors. Currently the theory is that GO interferes with the signalling pathways in the cell membranes, curbing the proliferation mechanism.

Interestingly, this graphene derivative had already been researched for as a targeted delivery vehicle in tumors, but has now been found to have an important effect itself on the tumor.

While the researchers acknowledge that the mechanisms at play need to be researched more before the material can be used to treat cancers, the ability to destroy cancer stem cells is an an important component of a cancer treatment protocol that kills existing tumors as well as shuts down future metatasis.

Vijayaraghavan and the Graphene Institute have previously made headlines as a recipient of research money from the Bill and Melinda Gates Foundation towards the development of a better condom. Their proposal, of course, used graphene.

The team's research was originally published in Oncotarget on February 24, 2015.

Source: University of Manchester

Read more here:
Graphene derivative interferes with seemingly invincible cancer stem cells

World News Videos | US News VideosCopy

A stem cell research breakthrough might someday allow same-sex couples to have their own biological children.

Researchers at Cambridge University in England have taken the first steps towards creating artificial sperm and eggs by reprogramming skin cells from adults and converting them into embryonic-like stem cells. The team then compared the engineered stem cells with human cells from fetuses to confirm they were in fact, identical.

The researchers published their findings in the journal Cell earlier this week, stressing that its early days for this type of research.

We have succeeded in the first and most important step of the process, Dr. Jacob Hanna, an investigator with the Weizmann Institute of Science in Israel, told ABC News.

Hanna said the team will now attempt to complete the process by creating fully developed artificial sperm and eggs, either in a dish or by implanting them in a rodent. Once this is achieved, the technique could become useful for any individual with fertility problems, he said, including couples of the same sex.

"It has already caused interest from gay groups because of the possibility of making egg and sperm cells from parents of the same sex," Hanna said.

However, the prospect of creating a baby by these artificial means alone is probably a long way off, Hanna said.

It is really important to emphasize that while this scenario might be technically possible and feasible, it is remote at this stage and many challenges need to be overcome, he said. Further, there are very serious ethical and safety issues to be considered when and if such scenarios become considered in the distant future.

The research was funded by the Wellcome Trust and the Britain Israel Research and Academic Exchange Partnership.

Read more here:
The Reason Same-Sex Couples May One Day Have Biological Kids

Bengaluru, Feb 25, 2015, dhns:

Two courses of stem cell therapy have helped Ashok Kumar, 59, who suffered from tremors and rigidity due to Parkinsons disease, recover completely, much to the joy of his family.

The man was brought inside my cabin in a wheelchair. He was unable to even sit on the chair without support. Today, he walks independently. Stem cell therapy has made it possible for him, said Dr Naseem Sadiq, Director, Plexus Neuro and Stem Cell Research Centre, who began treating Kumar in October, last year.

Previously, medication and surgical procedure were the only treatment option for Parkinsons disease. Medication in the long-term often lacks effectiveness and may cause side effects, while surgery is not always feasible. Lately, stem cell therapy has turned out to be a boon for patients with Parkinsons, Dr Sadiq said.

Kumar is among the few who have benefited from stem cell therapy. However, though the State has been reporting an increase in the number of registered stem cell donors, it is far behind sufficient as the genetic match between donor and recipient could be anywhere between one in 10,000 and one in two million, according to experts.

Speaking to Deccan Herald, Raghu Rajgopal, co-founder, Datri, a registry for stem cell donation, said, The response we get from Karnataka when we conduct stem cell camps is great. We see a lot of people and registering with us.

As many as 6,000 people have registered from the State under the Datri registry. A total of 72,000 people have registered across the country. In Kerala, 11,000 have signed up, the highest so far, he said.

Among the common myths are that by donating stem cells one turns infertile and weak, have increased chances of cancer and also that there would be excess loss of blood, he said.

According to studies, over one lakh people are diagnosed with Leukemia (blood cancer) and other blood disorders every year in India.

The Indian Council of Medical Research has predicted that by the end of 2015, Leukemia cases will reach an estimated 1,17,649 and 1,32,574 by 2020. Stem cell therapy is a widely used treatment mechanism for Leukemia.

Excerpt from:
Stem cell therapy a boon for Parkinson patients

Contact Information

Available for logged-in reporters only

Newswise STRATFORD Paola Leone, PhD, the director of the Cell and Gene Therapy Center and a professor of Cell Biology at the Rowan University School of Osteopathic Medicine (RowanSOM), has been awarded a three-year, $477,000 grant from the National Institute of Neurological Disorders and Stroke (NINDS) to develop a stem cell-based therapy for Canavan disease, a rare but devastating neurological disorder in children that typically takes a childs life by age 10.

Canavan disease is a fatal, inherited disease caused by a mutation in the aspartaocylase gene, Dr. Leone explained. The disease is characterized by progressive and severe brain atrophy that manifests in delayed development, developmental regression, microcephaly, spasticity, seizures, visual impairment and short life expectancy. There, currently, is no treatment or cure for Canavan disease.

Under Dr. Leones direction, a team of RowanSOM researchers and students will examine the potential of stem cells for the treatment of Canavan disease in an animal model. This new study will build on the research teams preliminary data that demonstrated the successful engraftment of stem cells in animal models.

Our project will generate pre-clinical data to support the development of a stem-cell based therapy for Canavan disease, Dr. Leone said. It will also provide an important opportunity for a new generation of clinical researchers. Both undergraduate and graduate students will participate in this project, providing them with valuable experience to work with an extremely promising therapeutic intervention.

The symptoms of Canavan disease usually appear within the first six months of a childs life. The disease is caused by a genetic mutation that stops cells, called oligodendrocytes, from developing myelin, the fatty substance that coats the nerves in the brain. Without the protective myelin covering, the nerves do not form properly, causing the brain to atrophy. The preliminary research that Dr. Leone conducted showed that the engraftment of stem cells promoted significant recovery of the myelin sheath surrounding the nerves.

Our research represents a significant departure from other studies that have focused solely on strategies to augment the loss of the aspartaocylase function that is highly reduced in the brains of these patients, Dr. Leone said. We believe that any strategy seeking to treat Canavan must include a way to restore the myelin development that is disrupted in children with this disease.

This research is supported by the NINDS of the National Institutes of Health, under grant number 1R15NS088763-01A1.

Journalists wishing to speak with Dr. Leone, should contact Jerry Carey, Rowan University Media and Public Relations at 856-566-6171 or at careyge@rowan.edu.

See the rest here:
Rowan Researcher Targets Stem Cell-Based Therapy for Rare Childhood Disease

U.S. and Australian scientists have found the mechanism a novel gene uses to affect brain function and elicit behavior related to neuropsychiatric disease.

Timothy W. Bredy, assistant professor of neurobiology & behavior at UC Irvine, and colleagues at the University of Queensland and the Garvan Institute of Medical Research in Sydney discovered that a gene called Gomafu might be key to understanding how our brain rapidly responds to stressful experiences.

By looking across the entire genome for genes that are responsive to experience, they found Gomafu -- which has recently been associated with schizophrenia -- to be dynamically regulated in the adult brain.

"When Gomafu is turned off, this results in the kind of behavioural changes that are seen in anxiety and schizophrenia," said Bredy, who is also affiliated with UCI's Center for the Neurobiology of Learning and Memory and UQ's Queensland Brain Institute.

The gene is a long, noncoding RNA and was found within a section of the genome most commonly associated with "junk" DNA -- the 98 per cent of the human genome that, until recently, was thought to have no function. This is the first time long, noncoding RNA activity has been detected in the brain in response to experience

"Early biologists thought that DNA sequences that do not make protein were remnants of our evolutionary history, but the fact is these sequences are actually highly dynamic and exert a profound influence on us," Bredy said.

Bredy and colleagues also found that noncoding genes such as Gomafu might represent a potent surveillance system that has evolved so that the brain can rapidly respond to changes in the environment. He added that a disruption of this network in the brain might contribute to the development of neuropsychiatric disorders.

These findings also will help to resolve the current controversy surrounding genome-wide association studies, where the majority of gene mutations that correlate with specific neuropsychiatric disorders are found within vast stretches of noncoding DNA sequences.

The scientists hope this finding will enable better prediction of vulnerability and resilience to developing a neuropsychiatric disease, with the primary goal to garner better treatment approaches across the lifespan.

Study results appeared online Feb. 10 in Biological Psychiatry.

Read more:
Hidden gene gives hope for improving brain function

13 hours ago This is a figure depicting four regulatory models for genome-edited crops. Credit: Araki, M. and Ishii, T./Trends in Plant Science 2015

A survey of rice, wheat, barley, fruit, and vegetable crops found that most mutants created by advanced genetic engineering techniques may be out of the scope of current genetically modified organism (GMO) regulations. In a review of these findings, published in the February 25 issue of the Cell Press journal Trends in Plant Science, two bioethicists from Hokkaido University propose new regulatory models for genome-edited crops and declare a call to action for clarifying the social issues associated with such genetically engineered crops.

"Modern genome editing technology has allowed for far more efficient gene modification, potentially impacting future agriculture," says Tetsuya Ishii, PhD, of Hokkaido University's Office of Health and Safety. "However, genome editing raises a regulatory issue by creating indistinct boundaries in GMO regulations because the advanced genetic engineering can, without introducing new genetic material, make a gene modification which is similar to a naturally occurring mutation."

Under current regulations, a GMO is a living organism that has been altered by a novel combination of genetic material, including the introduction of a transgene. Advanced genetic engineering technologies, including ZFN, TALEN, and CRISPR/Cas9, raise regulatory issues because they don't require transgenes to make alterations to the genome. They can simply pluck out a short DNA sequence or add a mutation to an existing gene.

"Genome editing technology is advancing rapidly; therefore it is timely to review the regulatory system for plant breeding by genome editing," says Dr. Ishii. "Moreover, we need to clarify the differences between older genetic engineering techniques and modern genome editing, and shed light on various issues towards social acceptance of genome edited crops."

In their study, Dr. Ishii and a member of his research staff, Motoko Araki, present four regulatory models in order to resolve the indistinct regulatory boundaries that genome editing has created in GMO regulations. They propose that the most stringent regulation (in which most of the mutants are subject to the regulations, whereas only a portion of deletion and insertion mutants fall outside the regulations) should be initially adopted and gradually relaxed because the cultivation and food consumption of genome-edited crops is likely to increase in the near future.

While policy-level discussions about the regulations of genome-edited organisms are slowly taking place around the world, according to Dr. Ishii, his study will serve as a basis for the conversation with regulatory agencies in the world as well as the Japanese Ministry of the Environment.

Explore further: Coming soon: Genetically edited fruit?

Recent advances that allow the precise editing of genomes now raise the possibility that fruit and other crops might be genetically improved without the need to introduce foreign genes, according to researchers writing in ...

One of the most exciting scientific advances made in recent years is CRISPRthe ability to precisely edit the genome of cells. However, although this method has incredible potential, the process is extremely inefficient. ...

Originally posted here:
Regulating genome-edited crops that aren't GMOs

Contact Information

Available for logged-in reporters only

Newswise The therapeutic promise of human stem cells is indisputably huge, but the process of translating their potential into effective, real-world treatments involves deciphering and resolving a host of daunting complexities.

Writing in the February 25 online issue of the journal PLOS ONE, researchers at University of California, San Diego School of Medicine, with collaborators from The Scripps Research Institute (TSRI), have definitively shown for the first time that the culture conditions in which stem cells are grown and mass-produced can affect their genetic stability.

Since genetic and epigenetic instability are associated with cancers, we worry that similar alterations in stem cells may affect their safety in therapeutic transplants. Certain mutations might make transplanted stem cells more likely to form tumors, introducing the risk of cancer where it didnt exist before, said co-corresponding author Louise Laurent, MD, PhD, assistant professor and director of perinatal research in the Department of Reproductive Medicine at UC San Diego School of Medicine.

This study shows the importance of quality control, added Jeanne F. Loring, PhD, professor and director of the Center for Regenerative Medicine at TSRI, and adjunct professor in the UC San Diego Department of Reproductive Medicine and the studys other co-corresponding author. Its almost certain these cells are safe, but we want to make sure they are free from any abnormalities.

To exploit the transformative powers of human pluripotent stem cells, which include embryonic stem cells and induced pluripotent stem cells, requires producing them in large numbers for transplantation into patients.

During this culturing process, mutations can occur, and mutations that increase cell survival or proliferation may be favored, such that the cells carrying such mutations could take over the culture, said Laurent.

Human pluripotent stem cells are cultured in several different ways. Key variables are the surfaces upon which the cells are cultured, called the substrate, and the methods used to transfer cells from one culture dish into another as they grow, called the passage method.

Originally, scientists determined that stem cells grew best when cultured atop of a feeder layer that included other types of cells, such as irradiated mouse embryonic fibroblasts. For reasons not fully understood, these cells provide stem cells with factors that support their growth. However, concerns about the feeder cells also introducing undesirable materials into stem cells has prompted development of feeder-free cultures.

Visit link:
Culture Clash: How Stem Cells Are Grown Affects Their Genetic Stability

Relief from peripheral neuropathy, spinal cord injury, foot and leg pain and balance issues
In late 2013 Kevin suffered a spinal cord injury, called an abcess. He was paraplegic and was told by 4 neurosurgeons that he would never be able to walk again. He began walking on his own,...

By: Arizona Chiropractic Neurology Center

Originally posted here:
Relief from peripheral neuropathy, spinal cord injury, foot and leg pain and balance issues - Video

Forth Worth, Texas (PRWEB) February 25, 2015

Board Certified Anesthesiology and Pain Medicine physicians, Scott Berlin, M.D., Andrew Cottingham, M.D., and Michael Scott Phillips, M.D. have created a new division of Pinnacle Pain Medicine offering state of the art biologic therapies to the Dallas-Ft. Worth Metropex. The new division, called OPTIMAL Pain & Regenerative Medicine, will provide pain management and regenerative therapies at offices in Alliance, Arlington, Burleson, Cleburne and Ft. Worth. These therapies, - Platelet Rich Plasma (PRP) and Bone Marrow Aspirate Concentrate (BMAC) - are used to treat neck and back pain, arthritis, joint and soft-tissue injuries and sports related injuries.

It is estimated that 116 million American adults will suffer from some degree of chronic pain during their lives. Since pain is debilitating both physically and emotionally, it is important to manage it the right way. Traditionally, patients seeking relief from pain are treated with injection/interventional therapy, implantable therapies, medication management and physical therapy.

For patients whose pain cannot be successfully managed with these treatments and therapies, Regenerative Medicine may offer new hope. OPTIMAL currently offers two forms of regenerative treatments, platelet-rich plasma (PRP) and bone marrow aspirate concentrate (BMAC). PRP and BMAC are both non-surgical treatment options that use the bodys natural healing abilities to accelerate the treatment of back pain, joint, tendon and ligament injuries.

Platelet-Rich Plasma, commonly known as PRP, is an advanced regenerative therapy that uses the patients own blood components to help rebuild damaged tissue. First, blood is drawn and separated by a centrifuge device to create a concentrate of platelets in plasma. This platelet concentrate contains multiple growth factors that are essential in inducing and accelerating tissue repair and regeneration. Using the most advanced tissue guidance with ultrasound, the PRP concentrate is then injected into the damaged areas including connective tissues, bone, and hyaline cartilages to expedite the development of new blood vessels necessary for tissue healing.

A more advanced form of regenerative therapy is bone marrow aspirate concentrate, BMAC. Through a simple outpatient procedure, BMAC involves the removal of the patients own bone marrow from the pelvic bones (Iliac crest). This bone marrow is concentrated to contain all of the growth and healing factors that are contained in PRP, along with concentrated pluripotent (stem-like) nucleated cells that further contribute to the regenerative process. BMAC is used to help regenerate joint cartilage and spinal discs and may significantly speed the healing process for other injuries. It is often used in cases with significant tissue damage, or when other types of regenerative therapies have failed.

Regenerative medicine is on the forefront of innovative treatment. To date, many professional athletes, amateur and collegiate athletes around that world have been successfully treated with PRP and BMAC. If you are interested in exploring the treatment options for regenerative medicine, please contact us at 817-472-2140 or visit our website at OptimalDFW.com.

About Our Doctors

Drs. Scott Berlin, Andrew Cottingham and Michael Phillips are all double board certified in anesthesiology and pain medicine. Dr. Berlin was the first practitioner in Dallas to implant a fully implantable dual lead spinal cord stimulator system, which has now become the standard of care. Dr. Cottingham has been working exclusively in pain medicine since 2003, by providing comprehensive interventional pain therapies to patient in North Texas. Dr. Phillips began practicing both anesthesiology and pain medicine in 1999 and began practicing pain medicine exclusively in 2007. Dr. Phillips was the first physician in the Dallas-Fort Worth area to perform the intradiscal BMAC procedure.

View post:
OPTIMAL Pain & Regenerative Medicine Brings Cutting Edge Platelet Rich Plasma (PRP) and Bone Marrow Aspirate ...

It's the fifth most common type of cancer in U.S. adults. For years, traditional therapies to treat 'non-Hodgkin's lymphoma (NHL) have included chemotherapy, radiation and a stem cell/bone marrow transplant. For the first time, a promising new option will be offered at Nebraska Medicine called Chimeric Antigen Receptor (CAR T-Cell Therapy). It's a way of taking the patient's own immune system and modifying it to attack the cancer.

"T cells are white blood cells that help our bodies fight infection and cancer," explains Julie Vose, MD, chief of hematology/oncology at Nebraska Medicine. "In lymphoma patients, these cells have gone haywire. They don't fight the cancer properly. This clinical trial will allow us to take the patient's own T cells outside the body and restimulate them to be able to fight their own lymphoma."

From start to finish, the entire process takes about three weeks. During the first phase, the patient's T cells are collected during an outpatient procedure at the hospital. The cells are then sent to a lab in California for processing. In the meantime, the patient receives several days of intense chemotherapy. When the cells return to Omaha, they're placed in a specialized processing center at Nebraska Medicine to complete the procedure. The patient then has their own modified T cells given back to them. A specialized team monitors the patient at the hospital for the next 7-10 days, including frequent blood tests and exams.

"It's a great opportunity for non-Hodgkin's lymphoma patients who have failed every other therapy," says Dr. Vose. "So far, this clinical trial has only been done in a few patients, but it looks very promising with high response rates."

In the past, CAR T-Cell Therapy has only been offered at a few places, including Memorial Sloan Kettering Cancer Center in New York, University of Washington Medical Center in Seattle, and the Hospital of the University of Pennsylvania in Philadelphia. Nebraska Medicine is one of the first hospitals in the Midwest to offer the clinical trial.

"This type of treatment can't be done at just any hospital or center. It's specialized with respect to what's needed to collect and process the cells," explains Dr. Vose. "We have a very large lymphoma program at Nebraska Medicine, which specializes in research and clinical trials. We're hoping to attract patients from all over the region."

The clinical trial is open to adult patients (19 years and older) with relapsed b-cell lymphomas, which is a subtype of non-Hodgkin's lymphoma. Because the treatment is extensive, the patient must be in good enough shape. Some of the treatment aspects are paid for by the study. Dr. Vose is looking to attract 5-10 participants over the next year, but will take more if interest is high.

See original here:
New Therapy Offered For Non-Hodgkin's Lymphoma Patients

Durham, NC (PRWEB) February 25, 2015

A new study published in the latest issue of STEM CELLS Translational Medicine reveals how a particular type of stem cell generated from fat tissue may outperform other types of stem cells in speeding up the healing of wounds caused by type 1 diabetes. In the study, ulcers in a mice model treated with these cells healed significantly faster than those treated with general types of stem cells.

Slow-healing wounds present one of the most common and perplexing complications associated with both type 1 and type 2 diabetes. If left untreated, they can lead to amputation, and even death. In fact, diabetes is the leading cause of non-traumatic lower limb amputation in the United States, according to the American Diabetes Association. Despite this, there are very few consistently effective treatments for speeding the wound-healing process in patients.

Addressing this issue, researchers at the University of Tokyo (UT) School of Medicine partnered with colleagues at the Research Center for Stem Cell Engineering, National Institute for Advanced Industrial Science and Technology (Ibaraki, Japan) to test whether a type of mesenchymal stem cell (MSC) called Muse, which is harvested from adult adipose tissue (that is, fat), might work better than other types of MSCs in treating diabetes wounds. Previous studies had shown that Muse which stands for multilineage differentiating stress-enduring cells do not have high proliferative activity, but they do generate multiple cell types of the three germ layers without inducing unfavorable tumors. Thus, Muse cells appear to be safer than other induced pluripotent or multipotent cells and might have better therapeutic potential than general (non-Muse) MSCs.

The study details how researchers isolated the Muse cells from human tissue and then injected them into skin ulcers in diabetic mice. Study leader Kotaro Yoshimura, M.D., of UTs Department of Plastic Surgery said that, After 14 days the mice treated with Muse-rich cells showed significantly accelerated wound healing compared to those treated with Muse-poor cells. The transplanted cells were integrated into the regenerated skin as vascular endothelial cells and other cells. However, they were not detected in the surrounding intact regions.

In fact, not only had the wounds of the mice treated with the Muse cells completely healed after the 14-day period, but the healed skin was thicker than that of the non-Muse treated wounds, too.

Were not sure yet why the Muse cells seem to work better, Dr. Yoshimura stated, but they expressed upregulated pluripotency markers and some angiogenic growth factors, and our animal results certainly suggest a clinical potential for them in the future. These cells can be achieved in large amounts with minimal morbidity and could be a practical tool for a variety of stem cell-depleted or ischemic conditions of various organs and tissues.

Fat tissue has been gaining attention as a practical source of adult stem cells, said Anthony Atala, M.D., Editor-in-Chief of STEM CELLS Translational Medicine and director of the Wake Forest Institute for Regenerative Medicine. This study suggests the future clinical potential for Muse cells.

###

The full article, Therapeutic Potential of Adipose-Derived SSEA-3-Positive Muse Cells for Treating Diabetic Skin Ulcers, can be accessed at http://www.stemcellstm.com.

Read the original post:
Researchers Hone in on Stem Cell that Speeds Healing of Stubborn Diabetes Wounds

Kyoto University Hospital says it will open a center to conduct clinical studies on induced pluripotent stem cell therapies in 2019 year.

Officials said the 30-bed ward will test the efficacy and safety of the therapies on volunteer patients.

The hospital aims to break ground at the site next February and complete construction by September 2019.

As an iPS cell research hub, we hope to apply (the cells) to groundbreaking therapies and make developments in the field of drug discovery, the hospital said in a statement Monday.

Ongoing research on iPS cells at Kyoto University includes turning the cells into dopamine-releasing neurons for transplant into patients with Parkinsons disease, and creating a formulation of platelets that helps blood to clot.

Professor Shinya Yamanaka, who shared the 2012 Nobel Prize in medicine, leads the existing iPS cell research center at Kyoto University.

Follow this link:
Kyoto University Hospital to open iPS cell therapy center in 2019

Jeanne Loring holds a petri dish with induced pluripotent stem cells from a Parkinsons patient.

A nine-year legal challenge to human embryonic stem cell patents ended Tuesday, when the Supreme Court declined to hear the case.

The decision means the Wisconsin Alumni Research Foundation, or WARF, will get to keep its patent rights for the cells, which were discovered in 1998 by University of Wisconsin - Madison scientist James Thompson.

However, the challengers succeeded in preventing WARF from gaining rights over another important type of stem cells called induced pluripotent stem cells, said Jeanne Loring, a stem cell scientist at The Scripps Research Institute in La Jolla who was part of a coalition contesting the WARF patents.

IPS cells act much like human embryonic stem cells, and are being researched as an alternative for stem cell therapy. Loring is working with a group that seeks to use them to treat Parkinson's disease.

WARF maintains it has the right to license use of human embryonic stem cells, because Thompson developed the methods to isolate them from embryos, which had not been previously done. Loring said the derivation is an obvious extension of methods used to derive non-primate embryonic stem cells, and therefore not patentable.

Loring and two public interest groups, Consumer Watchdog and the Public Patent Foundation, challenged the patents in 2006, and in 2007 succeeded in narrowing WARF's claims to exclude the IPS cells. Loring and the groups continued the challenge on the grounds that as a product of nature, human embryonic stem cells are not patentable.

The U.S. Patent and Trade Office turned down that challenge, and the case reached the Supreme Court last year. By not hearing the case, the Supreme Court let that decision stand.

"They still own human embryonic stem cells," Loring said. "But the way their patents were originally written, they would have also been able to own IPS cells. If there's one success that I would point to, that was worth all the effort, it's that they can't. And the reason they can't is because we challenged the patent."

Calls and an email sent Tuesday to WARF headquarters in Madison, Wis., were not immediately returned.

Read this article:
Supreme Court rejects stem cell patent case

A clinical trial using T-cell therapy that uses the patients' own immune cells to hunt down cancer cells is now being offered at the University of Michigan's C.S. Mott Children's Hospital.

"For patients for whom we've exhausted all other options, this therapy has provided hope against a highly aggressive form of ALL, in situations where nothing else has been successful," says John Levine, M.D., clinical director of the Pediatric Blood and Marrow Transplantation Program at C.S. Mott Children's Hospital.

To begin the treatment process, researchers first extract a patient's own T cells. They then use bioengineering techniques to reprogram each patient's T cells into chimeric antigen receptor cells -- the CTL019 cells -- custom-designed to bind to a protein called CD19 that exists only on the surface of B cells. After being returned to the patient's body, the CTL019 cells proliferate and then hunt B cells that express CD19. They also may persist in the circulation, which may guard against the cancer's recurrence.

"We are very proud to play an active role in this exciting new research that can offer new breakthroughs and hope for our pediatric cancer patients," says Levine, a professor of pediatrics in the University of Michigan Medical School.

In July 2014, the U.S. Food and Drug Administration designated CTL019 as a Breakthrough Therapy, helping to expedite its progress into broader clinical trials.

The trial opened in late October at Mott. Patients interested in participating should contact the center at 1-800-865-1125 to determine their eligibility.

Side effects from the treatment can include symptoms of cytokine release syndrome (CRS), which occurs when CAR cells and multiply in the patient's body resulting in the release of cytokines. CRS symptoms include varying degrees of flu-like symptoms with high fevers, nausea, muscle pain, and in some cases, low blood pressure and breathing difficulties.

Story Source:

The above story is based on materials provided by University of Michigan Health System. Note: Materials may be edited for content and length.

Excerpt from:
T-cell therapy clinical trial now offered to cancer patients in Michigan

Children with acute lymphoblastic leukemia who had a certain gene variant experienced a higher incidence and severity of peripheral neuropathy after receiving treatment with the cancer drug vincristine, according to a study in the February 24 issue of JAMA.

Cancer remains the leading cause of death by disease in U.S. children despite major advances in the last 20 years. Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, and as cure rates have surpassed 85 percent, it becomes increasingly important to lessen the toxicities of treatment that adversely affect quality of life and longevity. Vincristine is one of the most widely used and effective anticancer agents for treating leukemias in both adults and children. The dose-limiting toxic effect of vincristine is peripheral neuropathy (damage to the nerves), characterized by neuropathic (nerve) pain and impaired manual dexterity, balance, and altered gait. Currently, there are no reliable means of identifying patients at high risk of vincristineinduced neuropathy nor strategies to reduce this drug toxicity, according to background information in the article.

William E. Evans, Pharm.D., of St. Jude Children's Research Hospital, Memphis, and colleagues performed a genome-wide association study to determine whether there are genetic variants associated with vincristine-induced neuropathy. The study included patients in 1 of 2 prospective clinical trials for childhood ALL that included treatment with 36 to 39 doses of vincristine. Genetic analysis and vincristine-induced peripheral neuropathy were assessed in 321 patients from whom DNA was available: 222 patients (median age, 6.0 years) enrolled in 1994-1998 in a St. Jude Children's Research Hospital cohort; and 99 patients (median age, 11.4 years) enrolled in 2007-2010 in a Children's Oncology Group (COG) cohort.

Grade 2 (moderate) to 4 (life threatening) vincristine-induced neuropathy during therapy occurred in 28.8 percent of patients (64/222) in the St. Jude cohort and in 22.2 percent (22/99) in the COG cohort. The researchers found that an inherited variant in the gene CEP72 was associated with a higher incidence and severity of vincristine-related peripheral neuropathy in children with ALL. Among patients with the gene variant, 28 of 50 (56 percent) developed at least 1 episode of grade 2 to 4 neuropathy, compared with 21 percent (58/271) of other patients.

"If replicated in additional populations, this finding may provide a basis for safer dosing of this widely prescribed anticancer agent," the authors write.

Editorial: Precision Medicine to Improve the Risk and Benefit of Cancer Care

"The study by Diouf et al has many key elements; genome-wide discovery in patients from well-conducted clinical trials, replication in a multicenter cohort, statistical robustness, and laboratory correlative findings that contribute biologic plausibility," writes Howard L. McLeod, Pharm.D., of the Moffitt Cancer Center, Tampa, Fla., in an accompanying editorial.

"However, vincristine remains a component of the most widely accepted treatment regimens for childhood ALL, although there is variation in both dose and intensity. It is not clear that vincristine can be removed from the treatment options for a child with CEP72 variants, although this study suggests that the resulting increase in leukemia cellular sensitivity makes vincristine dose reductions possible without compromising antileukemic effect."

"However, there is value in the association of CEP72 with vincristine-induced peripheral neuropathy (VIPN). The ability to objectively ascribe a degree of heightened VIPN risk will allow for greater transparency in discussions of risk and benefits of therapy with patients and their family members. This also may lead to developmental therapeutic approaches to modulate CEP72 function as either primary prevention or treatment of chronic VIPN. This study also represents an initial robust effort to generate predictors for adverse drug reactions in cancer care."

Story Source:

More here:
Gene variant, risk, severity of nerve disorder linked to cancer drug

Contact Information

Available for logged-in reporters only

Newswise (MEMPHIS, Tenn. February 24, 2015) Researchers have identified the first genetic variation that is associated with increased risk and severity of peripheral neuropathy following treatment with a widely used anti-cancer drug. Investigators also found evidence of how it may be possible to protect young leukemia patients without jeopardizing cures. St. Jude Childrens Research Hospital scientists led the study, which appears today in the Journal of the American Medical Association.

The study involved 321 children and adolescents whose acute lymphoblastic leukemia (ALL) treatment included between 36 and 39 doses of the drug vincristine.

Researchers screened patient DNA for almost 1 million common inherited genetic variations and found that 60.8 percent of those who inherited two copies of a variation in a gene named CEP72 developed peripheral neuropathy. Vincristine-related peripheral neuropathy was diagnosed in 23.4 percent of patients who inherited at least one of the more common versions of CEP72. Patients with two copies of the high-risk CEP72 variant were also more than twice as likely as other patients to experience serious, disabling or life-threatening peripheral neuropathy.

The newly identified CEP72 variant also increased the sensitivity of cancer cells to vincristine. That suggests it might be possible to lower the vincristine dose in these patients without compromising the likelihood of cures, said the corresponding author William Evans, Pharm.D., a member of the St. Jude Department of Pharmaceutical Sciences. The possibility will be studied in a St. Jude clinical trial scheduled to open later this year for newly diagnosed pediatric ALL patients.

St. Jude researchers have already achieved high cure rates for ALL. In this study, they identified a possible reason why some people experience a serious side effect of the medicationdebilitating nerve pain, said Rochelle Long, Ph.D., director of the National Institutes of Health Pharmacogenomics Research Network. This genetic insight will help scientists devise treatment plans that ensure safety and effectiveness as well as the long-term quality of life for children with ALL.

Vincristine is one of the most widely used and effective agents for treatment of leukemia, lymphoma, brain and solid tumors in children and adults. But in a significant number of children and adults, the drug causes episodes of peripheral neuropathy that can become chronic and resurface in adulthood. The symptoms, which include pain, numbness and other changes that make walking difficult, are often severe enough to delay treatment. Such delays can compromise the likelihood of a cure. Currently there is no way to identify patients who are most likely to develop the nerve damage.

Overall 50 patients, or 16 percent of 321 those in this study, inherited two copies of the high-risk CEP72 variant. The study included 222 newly diagnosed patients enrolled in the St. Jude Total XIIIB clinical trial between 1994 and 1998. The remaining 99 patients were part of a Childrens Oncology Group (COG) study for relapsed patients. COG is the worlds largest organization devoted exclusively to childhood and adolescent cancer research.

The high-risk CEP72 variant identified in this study was linked to a greater risk of peripheral neuropathy even when researchers took other risk factors into account, including race and vincristine dose. Vincristine-related peripheral neuropathy is less common among African-American patients. Researchers found that the high-risk version of the gene is also less common in African-American patients, so they are less likely than patients from other racial backgrounds to inherit the high-risk version of CEP72.

See original here:
Inherited Gene Variation Leaves Young Leukemia Patients at Risk for Peripheral Neuropathy

Boston, MA (PRWEB) February 25, 2015

Anyone familiar with the founding principles of Asymmetrex, LLC will appreciate the new editorial from its director and the collection of authors he assembled as Associate Editor for the Frontiers Research Topic, titled Stem Cell Genetic Fidelity. Both the introductory editorial and the individual articles are currently available online, ahead of issue in the form of the Frontiers e-book later this year.

Central to the stem cell mechanisms investigated and reviewed by the nine articles is the still controversial proposal of immortal strands in adult tissue stem cells. Based on the experimental observations of K. Gordon Lark in the 1960s, John Cairns predicted the existence of immortal strands of the DNA genetic material about a decade later.

In studies with cultured mouse tissues and plant root tips, Lark had noted that when some cells divided, they seemed to violate well-established genetic laws. These were the Mendelian laws of inheritance, name after Gregor Mendel, who laid their foundation. Each of the 46 human chromosomes has two complementary strands of DNA. One DNA strand is older than the other, because it was used as the template for copying the other. As a result of this inherent age difference in chromosome DNA strands, when the two DNA strands are split to make two new chromosomes before cell division to produce two new cells one chromosome in each of the 46 pairs of new chromosomes has the oldest DNA strand.

Mendels laws maintain that each new sister cell should randomly get a similar number of chromosomes with the oldest DNA strands. But Cairns hypothesized that adult tissue stem cells had a mechanism to ignore Mendels laws. Instead, one of the two cells produced by an asymmetric stem cell division retained all, and only, the chromosomes with the oldest DNA strands. Cairns called these immortal strands. By continuously retaining the same complete set of oldest template DNA strands, Cairns envisioned that tissue stem cells could significantly reduce their rate of accumulation of carcinogenic mutations, which primarily occur by chance when DNA is being copied.

Cairns presented his concept of immortal strands in tissue stem cells in a 1975 report to account for a large discrepancy that he had noted between human cancer rates and human cell mutation rates. He estimated that human cancer rates, though still undesirable, fell far short of expectations based on generally known rates of human cell mutation.

Whereas some scientists continue to view Cairns immortal strand hypothesis as folly, others consider it genius. In the last decade, progress in evidence for immortal strands in stem cells of diverse animal tissues and animal species accelerated greatly. However, little progress has occurred in defining their role in normal tissue stem cells or diseases like cancer.

In his new editorial, Sherley reveals that he is firmly in the camp that views the immortal strand hypothesis as genius. Before founding Asymmetrex, as a laboratory head in two different independent research institutes Fox Chase Cancer Center and Boston Biomedical Research Institute and at the Massachusetts Institute of Technology he developed new tools and approaches for investigating immortal strand functions, which are now a focus for commercial development in the new company. Immortal strands and cellular factors associated with them have significant potential to provide specific biomarkers for tissue stem cells. There is a significant unmet need for such invaluable tools in stem cell research, drug development, and regenerative medicine.

About Asymmetrex (http://asymmetrex.com/)

Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. Asymmetrexs founder and director, James L. Sherley, M.D., Ph.D. is an internationally recognized expert on the unique properties of adult tissue stem cells. The companys patent portfolio contains biotechnologies that solve the two main technical problems production and quantification that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. In addition, the portfolio includes novel technologies for isolating cancer stem cells and producing induced pluripotent stem cells for disease research purposes. Currently, Asymmetrexs focus is employing its technological advantages to develop facile methods for monitoring adult stem cell number and function in clinically important human tissues.

More here:
New Commentary from Asymmetrex LLC Director Anticipates Forthcoming E-Book on Stem Cell Genetic Fidelity

A Stem Cell Cure for Bubble Baby Disease (SCID)
Visit: http://www.uctv.tv/) On November 18th, 2014, a UCLA research team led by Donald Kohn, M.D., announced a breakthrough gene therapy and stem cell cure ...

By: University of California Television (UCTV)

See the rest here:
A Stem Cell Cure for Bubble Baby Disease (SCID) - Video